Our results are particularly important in light of the recent clinical validation of A20/tnfaip3 but also p21, SOCS3, and PPARα, as part of the integral regenerative response of the liver in the setting of LDLT [20], which supports our pursuit of A20-based therapies to improve the outcomes of LDLT, marginal liver grafts, and after extensive resections for tumor. The gene discussed is TNFAIP3; the disease is neoplasm.